

**formoterol 12 mcg metered dose inhaler  
(Easyhaler®)**

**(No. 375/07)**

**Ranbaxy (UK) Ltd**

**Product Update**

4 May 2007

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**Formoterol inhalation powder (Easyhaler® Formoterol)** is accepted for use within NHS Scotland for the treatment of asthma in patients treated with inhaled corticosteroids and who also require a long-acting beta<sub>2</sub>-agonist in accordance with current treatment guidelines; and for the relief of reversible airways obstruction in patients with chronic obstructive pulmonary disease (COPD) and requiring long-term bronchodilator therapy.

It should be used in patients for whom formoterol is an appropriate choice of long-acting beta<sub>2</sub>-agonist and a dry powder inhaler is an appropriate delivery device. It costs less than other inhalers delivering similar doses of formoterol.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 12 April 2007.*

**Chairman  
Scottish Medicines Consortium**